- PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
-
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
- -
-
Paragraph 0225-0226; 0231
(2020/11/23)
-
- AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
-
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
- -
-
Paragraph 000229; 000285; 000288
(2021/01/22)
-
- JAK-2 MODULATORS AND METHODS OF USE
-
This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention
- -
-
Page/Page column 119-120
(2008/06/13)
-
- UREA DERIVATIVE
-
The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R 2 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.
- -
-
Page/Page column 147
(2010/11/26)
-
- New indole derivatives with 5HT6 receptor affinity
-
This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: wherein one of R5, R6 or R7 is a group of general Formula B, wherein W is a —CH— group or a nitrogen
- -
-
-
- Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
-
The invention provides substituted phenyl compounds of general formula STR1wherein R 1, T, U and Ar are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
- -
-
-
- Adamantane derivatives
-
The invention provides compounds of general formula in which m, A, R1and Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
- -
-
-
- Solution phase combinatorial synthesis of arylpiperazines
-
A solution phase combinatorial synthesis of aryl piperazines 1 and 2 is described based on the S(N)Ar reaction and Schotten-Baumann acylation. The use of excess reagent is allowed and pure arylpiperazines 1 and 2 were obtained by simple acid/base washing.
- Neuville, Luc,Zhu, Jieping
-
p. 4091 - 4094
(2007/10/03)
-